Tarsons Products

  • Market Cap: Micro Cap
  • Industry: Healthcare Services
  • ISIN: INE144Z01023
  • NSEID: TARSONS
  • BSEID: 543399
INR
205.30
3.35 (1.66%)
BSENSE

Jun 12, 03:30 PM

BSE+NSE Vol: 63.88 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

63.88 k (6.53%) Volume

Shareholding (Mar 2026)

FII

0.87%

Held by 7 FIIs

DII

0.19%

Held by 0 DIIs

Promoter

47.30%

Why is Tarsons Products Ltd falling/rising?

13-Jun-2026

As of 12-Jun, Tarsons Products Ltd's stock price is rising to 205.30, reflecting a 1.66% increase. However, despite this short-term gain, the stock has significantly underperformed over the long term, with a year-to-date decline of 12.02% and weak fundamentals, indicating that the upward movement may not be sustainable.

As of 12-Jun, Tarsons Products Ltd's stock price is rising, currently at 205.30, reflecting a change of 3.35 (1.66%) upward. This increase comes after two consecutive days of decline, indicating a potential trend reversal. The stock touched an intraday high of Rs 208.35, which is a 3.17% increase from the previous close. <BR><BR>Despite the positive movement today, the stock has underperformed significantly over longer periods, with a year-to-date decline of 12.02% and a staggering 45.75% drop over the past year. Additionally, the stock's performance has been weak relative to the benchmark, with a consistent underperformance against the Sensex and BSE500 over the last three years. <BR><BR>Investor participation has shown some signs of improvement, with a notable increase in delivery volume by 67.84% compared to the 5-day average, suggesting a rise in trading interest. However, the stock's fundamentals remain weak, as evidenced by a negative return on equity and a decline in profits by 49% over the past year. Furthermore, institutional investors have reduced their stake in the company, indicating a lack of confidence in its long-term prospects.<BR><BR>In summary, while the stock is experiencing a short-term rise, the overall context of significant long-term underperformance and weak fundamentals suggests that this upward movement may not be sustainable.

View full answer

What does Tarsons Products do?

11-Jun-2026

Tarsons Products Ltd, a micro-cap company in the healthcare services industry, reported net sales of ₹121 Cr and a net profit of ₹4 Cr for the quarter ending March 2026. The company, incorporated in 1983 and publicly listed since June 2021, has a market cap of ₹1,142 Cr.

Overview:<BR>Tarsons Products Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Tarsons Products Limited was incorporated in 1983 as Tarsons Products Private Limited and later converted to a Public Limited Company on June 14, 2021. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 121 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 4 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 1,142 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 73.00 <BR>Industry P/E: 36 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.58 <BR>Return on Equity: 2.37% <BR>Price to Book: 1.82 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

View full answer

How big is Tarsons Products?

11-Jun-2026

As of 10th June, Tarsons Products Ltd has a market capitalization of 1,142.00 Cr, with recent net sales of 422.51 Cr and a net profit of 14.32 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Tarsons Products Ltd has a market capitalization of 1,142.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 422.51 Cr, while the sum of Net Profit for the same period is 14.32 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 630.21 Cr, and Total Assets are valued at 1,080.04 Cr.

View full answer

Who are in the management team of Tarsons Products?

11-Jun-2026

The management team of Tarsons Products includes Sanjive Sehgal (Chairman & Managing Director), Rohan Sehgal (Whole-time Director), Gaurav Podar (Nominee), and independent directors Viresh Oberai, Sucharita Basu, and Girish Paman Vanvari, along with Santosh Kumar Agrawal (Chief Finance Officer & Company Secretary).

The management team of Tarsons Products includes the following individuals:<BR><BR>1. **Sanjive Sehgal** - Chairman & Managing Director<BR>2. **Rohan Sehgal** - Whole-time Director<BR>3. **Gaurav Podar** - Nominee<BR>4. **Viresh Oberai** - Independent Director<BR>5. **Sucharita Basu** - Independent Director<BR>6. **Girish Paman Vanvari** - Independent Director<BR>7. **Santosh Kumar Agrawal** - Chief Finance Officer & Company Secretary<BR><BR>If you need more details about their roles or contributions, feel free to ask!

View full answer

Who are the peers of the Tarsons Products?

11-Jun-2026

Tarsons Products' peers include Krsnaa Diagnostics, Suraksha Diagnostics, Laxmi Dental, One Global Services, 3B Blackbio, Health X Platform, and Hemant Surgical. In terms of management risk, growth, and capital structure, Tarsons Products ranks below average, with a 1-year return of -45.32%.

Peers: The peers of Tarsons Products are Krsnaa Diagnost., Suraksha Diagno., Laxmi Dental, One Global Serv, 3B Blackbio, Health X Platfor, Hemant Surgical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Suraksha Diagno. and Hemant Surgical, while Average management risk is found at Krsnaa Diagnost., Laxmi Dental, One Global Serv, 3B Blackbio, and the rest. Below Average management risk is noted for Tarsons Products and Health X Platfor. Growth is Good at Suraksha Diagno., Laxmi Dental, and Hemant Surgical, while Average growth is seen at Health X Platfor, and Below Average growth is noted for Krsnaa Diagnost., Tarsons Products, 3B Blackbio, and the rest. Excellent capital structure is present at Krsnaa Diagnost., Laxmi Dental, One Global Serv, and Health X Platfor, while Good capital structure is found at Tarsons Products and Hemant Surgical, and Excellent capital structure is noted for 3B Blackbio.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Hemant Surgical at 278.57%, while the peer with the lowest is Laxmi Dental at -48.44%. Tarsons Products has a 1-year return of -45.32%, which is higher than Laxmi Dental but lower than Hemant Surgical. Additionally, Krsnaa Diagnost., Laxmi Dental, Tarsons Products, 3B Blackbio, and Health X Platfor all have negative six-month returns.

View full answer

Should I buy, sell or hold Tarsons Products Ltd?

27-May-2026

Are Tarsons Products Ltd latest results good or bad?

23-May-2026

Tarsons Products Ltd's latest Q4 FY26 results show strong revenue growth of 7.31% year-on-year, reaching ₹120.93 crores; however, a significant 59.02% decline in net profit and shrinking margins indicate serious operational challenges, making the overall performance concerning.

Tarsons Products Ltd's latest results for Q4 FY26 present a mixed picture, but overall, they lean towards being concerning. The company achieved its highest-ever quarterly revenue of ₹120.93 crores, reflecting a year-on-year growth of 7.31% and a sequential increase of 12.09%. However, this revenue growth is overshadowed by a significant decline in net profit, which fell to ₹4.18 crores, marking a drastic 59.02% decrease compared to the same quarter last year.<BR><BR>Additionally, the operating margin has contracted sharply, declining by 451 basis points to 28.34%. The profit after tax (PAT) margin also decreased to 3.46%, down from 9.05% in Q4 FY25. This deterioration in profitability is attributed to rising operational costs, including a 21.19% increase in employee expenses and a 45.18% rise in depreciation, which have outpaced revenue growth.<BR><BR>Moreover, the reliance on other income, which constituted a significant portion of profit before tax, raises concerns about the sustainability of the reported profitability. The overall financial performance indicates that while revenue growth is positive, the underlying operational challenges and declining profit margins suggest a troubling trend for the company. <BR><BR>In summary, while Tarsons Products has shown strong revenue growth, the sharp decline in profitability and margins indicates significant operational pressures, making the latest results more negative than positive.

View full answer

When is the next results date for Tarsons Products Ltd?

19-May-2026

The next results date for Tarsons Products Ltd is 22 May 2026.

The next results date for Tarsons Products Ltd is scheduled for 22 May 2026.

View full answer

Is Tarsons Products overvalued or undervalued?

02-Dec-2025

As of December 1, 2025, Tarsons Products is considered overvalued with a PE ratio of 59.27, significantly higher than its peers, and has underperformed the market with a year-to-date return of -43.36%.

As of 1 December 2025, the valuation grade for Tarsons Products has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a PE ratio of 59.27, an EV to EBIT of 40.66, and an EV to EBITDA of 13.33. These ratios suggest that the stock is trading at a premium compared to its earnings and cash flow generation capabilities.<BR><BR>In comparison to its peers, Tarsons Products' PE ratio is significantly higher than that of Finolex Industries, which stands at 22.79, indicating a stark contrast in valuation. Additionally, while Tarsons Products has a PEG ratio of 0.00, this is not favorable when compared to peers like Shaily Engineers, which has a PEG of 0.83, suggesting that Tarsons may not be justifying its high valuation through growth. The company's recent stock performance has been poor, with a year-to-date return of -43.36%, contrasting sharply with the Sensex's 9.60% return, further reinforcing the notion of overvaluation.

View full answer

How has been the historical performance of Tarsons Products?

13-Nov-2025

Tarsons Products has shown strong sales growth from 228.91 Cr in March 2021 to 392.41 Cr in March 2025, but profitability metrics, including profit before tax and profit after tax, have declined during the same period. Total assets increased significantly, while total debt rose sharply, indicating higher leverage.

Answer:<BR>The historical performance of Tarsons Products shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Tarsons Products has experienced notable changes in its financial performance from March 2021 to March 2025. Net sales increased from 228.91 Cr in March 2021 to 392.41 Cr in March 2025, indicating a strong growth trajectory. However, the total operating income followed a similar trend, rising from 228.91 Cr to 392.41 Cr during the same period. The total expenditure also rose significantly, from 125.48 Cr in March 2021 to 281.69 Cr in March 2025. Operating profit (PBDIT) peaked at 161.16 Cr in March 2022 but decreased to 126.68 Cr by March 2025. Profit before tax saw a decline from 92.43 Cr in March 2021 to 44.80 Cr in March 2025, while profit after tax also dropped from 68.87 Cr to 29.77 Cr in the same timeframe. The company's total assets increased from 295.95 Cr in March 2021 to 1,080.04 Cr in March 2025, reflecting substantial growth in its asset base. Conversely, total debt rose from 3.27 Cr to 328.56 Cr, indicating a significant increase in leverage. Overall, while Tarsons Products has shown growth in sales and assets, profitability metrics have declined in recent years.

View full answer

Is Tarsons Products technically bullish or bearish?

19-Aug-2025

As of 18 August 2025, Tarsons Products has shifted to a bearish trend with moderate strength, indicated by bearish MACD and Bollinger Bands across multiple time frames, along with significant underperformance against the Sensex.

As of 18 August 2025, the technical trend for Tarsons Products has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and a bearish daily moving average. The KST is mildly bearish on the weekly and bearish on the monthly, while the Dow Theory shows no trend on the weekly and mildly bearish on the monthly. The stock has underperformed significantly against the Sensex over various periods, further supporting the bearish outlook.

View full answer

Who are the top shareholders of the Tarsons Products?

06-Jun-2025

The top shareholders of Tarsons Products include Sanjive Sehgal with 26.98%, Clear Vision Investment Holdings Pte Limited at 23.42%, and 16 Foreign Institutional Investors holding a combined 9.52%. Individual investors own 15.3% of the shares.

The top shareholders of Tarsons Products include the promoters, with Sanjive Sehgal holding the highest stake at 26.98%. Additionally, Clear Vision Investment Holdings Pte Limited is the largest public shareholder, owning 23.42%. The company also has 16 Foreign Institutional Investors (FIIs) holding a combined 9.52% of the shares. Individual investors collectively hold 15.3% of the company's shares.

View full answer

Has Tarsons Products declared dividend?

06-Jun-2025

Yes, Tarsons Products Ltd has declared a 100% dividend, amounting to ₹2 per share, with an ex-date of September 20, 2024. However, the company has experienced negative total returns over various periods, indicating a decline in price performance despite the dividend declaration.

Tarsons Products Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 2<BR>- Ex-date: 20 Sep 24<BR><BR>Dividend Yield: 0.52%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -15.41%, the dividend return was 0%, resulting in a total return of -15.41%.<BR><BR>Over the past year, the price return was -8.35%, the dividend return was 0.47%, leading to a total return of -7.88%.<BR><BR>In the last 2 years, the price return was -33.53%, the dividend return was 0.35%, resulting in a total return of -33.18%.<BR><BR>For the 3-year period, the price return was -45.15%, the dividend return was 0.29%, culminating in a total return of -44.86%.<BR><BR>In the 4-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Over the last 5 years, both the price return and dividend return were 0%, leading to a total return of 0.0%.<BR><BR>Overall, while Tarsons Products has declared a dividend, the total returns over various periods indicate a negative trend in price performance, with minimal contributions from dividends.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Weak Long Term Fundamental Strength with a -39.98% CAGR growth in Operating Profits over the last 5 years

  • The company has been able to generate a Return on Equity (avg) of 6.24% signifying low profitability per unit of shareholders funds
2

The company has declared Negative results for the last 4 consecutive quarters

3

Falling Participation by Institutional Investors

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Healthcare Services

stock-summary
Market cap

INR 1,101 Cr (Micro Cap)

stock-summary
P/E

72.00

stock-summary
Industry P/E

35

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.58

stock-summary
Return on Equity

2.37%

stock-summary
Price to Book

1.68

Revenue and Profits:
Net Sales:
121 Cr
(Quarterly Results - Mar 2026)
Net Profit:
4 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.61%
0%
5.61%
6 Months
-10.21%
0%
-10.21%
1 Year
-45.75%
0%
-45.75%
2 Years
-55.29%
0.41%
-54.88%
3 Years
-63.14%
0.33%
-62.81%
4 Years
-71.51%
0.26%
-71.25%
5 Years
0%
0%
0.0%

Latest dividend: 2 per share ex-dividend date: Sep-20-2024

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

Announcements stock-summary

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

06-Jun-2026 | Source : BSE

Intimation of Schedule of Analyst/Institutional Investor Meeting(s)

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

06-Jun-2026 | Source : BSE

Intimation of Schedule of Analyst/Institutional Investor Meeting(s)

Intimation Under Regulation 30 Of SEBI LODR Regulations 2015 Regarding Equity Investment.

03-Jun-2026 | Source : BSE

Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Tarsons Products Ltd has declared 100% dividend, ex-date: 20 Sep 24

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
19.40%
EBIT Growth (5y)
-39.98%
EBIT to Interest (avg)
12.02
Debt to EBITDA (avg)
3.17
Net Debt to Equity (avg)
0.58
Sales to Capital Employed (avg)
0.37
Tax Ratio
34.61%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.06%
ROCE (avg)
5.13%
ROE (avg)
6.24%

Valuation key factors

Factor
Value
P/E Ratio
72
Industry P/E
35
Price to Book Value
1.72
EV to EBIT
68.10
EV to EBITDA
12.35
EV to Capital Employed
1.45
EV to Sales
3.45
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
2.13%
ROE (Latest)
2.37%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 2 Schemes (0.0%)

FIIs

Held by 7 FIIs (0.87%)

Promoter with highest holding

Sanjive Sehgal (26.98%)

Highest Public shareholder

Clear Vision Investment Holdings Pte Limited (23.42%)

Individual Investors Holdings

21.54%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 12.09% vs 5.43% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -17.06% vs 51.81% in Dec 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "120.93",
          "val2": "107.89",
          "chgp": "12.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "34.27",
          "val2": "31.52",
          "chgp": "8.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.25",
          "val2": "6.05",
          "chgp": "3.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.22",
          "val2": "-1.35",
          "chgp": "116.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4.18",
          "val2": "5.04",
          "chgp": "-17.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "28.34%",
          "val2": "29.21%",
          "chgp": "-0.87%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 4.70% vs 12.48% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -47.91% vs -13.44% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "151.79",
          "val2": "144.97",
          "chgp": "4.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "48.38",
          "val2": "40.52",
          "chgp": "19.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "8.69",
          "val2": "8.88",
          "chgp": "-2.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "10.10",
          "val2": "19.39",
          "chgp": "-47.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "31.87%",
          "val2": "27.95%",
          "chgp": "3.92%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 6.63% vs 15.98% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -36.33% vs -16.85% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "235.78",
          "val2": "221.13",
          "chgp": "6.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "77.52",
          "val2": "68.43",
          "chgp": "13.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "14.01",
          "val2": "13.01",
          "chgp": "7.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.35",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "17.19",
          "val2": "27.00",
          "chgp": "-36.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "32.88%",
          "val2": "30.95%",
          "chgp": "1.93%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 7.67% vs 32.40% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is -51.90% vs -30.18% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "422.51",
          "val2": "392.41",
          "chgp": "7.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "117.93",
          "val2": "110.72",
          "chgp": "6.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "22.55",
          "val2": "19.39",
          "chgp": "16.30%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.13",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "14.32",
          "val2": "29.77",
          "chgp": "-51.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "27.91%",
          "val2": "28.22%",
          "chgp": "-0.31%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQstock-summary

Mar'26
Dec'25
Change(%)
Net Sales
120.93
107.89
12.09%
Operating Profit (PBDIT) excl Other Income
34.27
31.52
8.72%
Interest
6.25
6.05
3.31%
Exceptional Items
0.22
-1.35
116.30%
Consolidate Net Profit
4.18
5.04
-17.06%
Operating Profit Margin (Excl OI)
28.34%
29.21%
-0.87%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is 12.09% vs 5.43% in Dec 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is -17.06% vs 51.81% in Dec 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
151.79
144.97
4.70%
Operating Profit (PBDIT) excl Other Income
48.38
40.52
19.40%
Interest
8.69
8.88
-2.14%
Exceptional Items
0.00
0.00
Standalone Net Profit
10.10
19.39
-47.91%
Operating Profit Margin (Excl OI)
31.87%
27.95%
3.92%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 4.70% vs 12.48% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is -47.91% vs -13.44% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
235.78
221.13
6.63%
Operating Profit (PBDIT) excl Other Income
77.52
68.43
13.28%
Interest
14.01
13.01
7.69%
Exceptional Items
-1.35
0.00
Standalone Net Profit
17.19
27.00
-36.33%
Operating Profit Margin (Excl OI)
32.88%
30.95%
1.93%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 6.63% vs 15.98% in Dec 2024

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2025 is -36.33% vs -16.85% in Dec 2024

Annual Results Snapshot (Consolidated) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
422.51
392.41
7.67%
Operating Profit (PBDIT) excl Other Income
117.93
110.72
6.51%
Interest
22.55
19.39
16.30%
Exceptional Items
-1.13
0.00
Consolidate Net Profit
14.32
29.77
-51.90%
Operating Profit Margin (Excl OI)
27.91%
28.22%
-0.31%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 7.67% vs 32.40% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2026 is -51.90% vs -30.18% in Mar 2025

stock-summaryCompany CV
About Tarsons Products Ltd stock-summary
stock-summary
Tarsons Products Ltd
Micro Cap
Healthcare Services
Tarsons Products Limited was incorporated as Tarsons Products Private Limited on July 5, 1983. The Company was subsequently converted into a Public Limited Company and the name of the Company was changed to Tarsons Products Limited on June 14, 2021.
Company Coordinates stock-summary
Icon
No Company Details Available